Axogen (AXGN) Q2 2026 Earnings Call Transcript
Axogen (AXGN) reported Q2 2026 revenue of $69.7 million, up 23.1% year over year, driven by growth in breast, extremities, and OMF. Breast revenue grew more than 50% and contributed about two-thirds of growth. Gross margin was 72.7%. Adjusted net income was $7.3 million ($0.12/share). Full-year revenue guidance raised to at least $279 million (24% growth) and gross margin to at least 73%.
How this was made
The 30-second read
Why it matters
The key tradable items are the raised full-year revenue target and the revised gross margin outlook, both explicitly linked to demand strength in breast procedures and higher costs from longer Avance grafts. Management also highlighted ongoing commercial expansion (sales force, high-potential accounts, surgeon training) and a minority investment in Trace Biosciences for nerve imaging technology.
Market read
Traders can update models for FY revenue and gross margin based on management’s guidance changes and the stated product mix and manufacturing cost drivers.
What to watch
Aetna coverage timing and the magnitude of production cost increases from updated third-quarter plans could be the swing factors for forward gross margin and free cash flow.
Background
This is Axogen’s Q2 2026 earnings call transcript with detailed segment performance, payer access commentary, and updated full-year guidance.
Ticker impact
Axogen reported Q2 revenue of $69.7M (+23.1% YoY) and raised full-year revenue guidance to at least $279M while revising gross margin guidance to at least 73%.
Likely near-term volatility as investors weigh stronger growth against margin pressure from product mix and higher Avance costs.
The call includes explicit guidance changes (revenue up, gross margin down) tied to a specific demand and manufacturing mix explanation, which typically drives re-rating but can temper earnings expectations.
Market effects
Signals continued reimbursement and adoption momentum in nerve repair products, with margin sensitivity to product mix.
US-focused payer coverage update (Aetna reviewing) may influence near-term demand expectations.
Limited direct global read-through; commentary is primarily US commercial execution and payer access.
Counterpoint
If Avance mix continues to skew toward longer grafts, gross margin could remain structurally pressured despite revenue growth.
Key entities
- companyAxogen, Inc.
US-listed medical device company reporting Q2 2026 results and updating FY revenue and gross margin guidance.
- companyTrace Biosciences
Company in which Axogen took a minority stake to develop Nervetrace nerve imaging technology.
- payerAetna
Commercial payer reviewing its coverage policy for Avance, with management targeting near-universal coverage if favorable.
